Company: INDP
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010099
Chunk: 62

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 2
Chunk 62
---
0
million of our common stock during a 36-month period, subject to the restrictions and satisfaction of the conditions in the SEPA. Upon
execution of the SEPA, we issued to Yorkville 305,960 commitment shares. During March 2025, we sold 1,605,200 shares of our common stock
under the SEPA for aggregate SEPA for aggregate net proceeds of approximately $1.15 million, after deducting offering expenses in the
amount of approximately $0.1 million.

In
January 2025, we completed a private placement for the sale and issuance by us of an aggregate of: (i) 2,109,383 shares of our common
stock and (ii) warrants to purchase 2,109,383 shares of common stock. The shares and warrants were sold on a combined basis for consideration
of $1.065 for one share and a warrant for aggregate gross proceeds of approximately $2.25 million.

In
November 2024, we completed a registered direct offering, pursuant to which we sold and issued to certain investors 1,817,017 shares
of our common stock in a registered direct offering. In addition, in a concurrent private placement, we issued to the investors unregistered
warrants to purchase 1,817,017 shares of common. The combined purchase price for one share of common stock and one warrant was $1.175,
resulting in gross proceeds of approximately $2.135 million.

In
August 2024, we completed a registered direct offering, pursuant to which we sold and issued to certain investors, 1,643,837 shares of
common stock. In addition, in a concurrent private placement, we issued to the investors unregistered warrants to purchase 1,643,837
shares of common stock. The combined purchase price for one share of common stock and one warrant was $1.825, resulting in gross proceeds
of approximately $3.0 million.

4

In
June 2022, we entered into an At The Market Offering Agreement (the “ATM Agreement”) which was amended on September 1, 2022
with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which we may offer and sell, from time to
time through Wainwright, shares of our common stock, par value $0.01 per share, for aggregate gross proceeds of up to $3.7 million. The
issuance